Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist:a dose-finding study
| Autor: | Manh Tuong Ho, Gia Bao Huynh, Peter Humaidan, Huy Tuan Phung, Tan Duc Ha, Thi Ngoc Lan Vuong |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Anti-Mullerian Hormone Pregnancy Rate medicine.medical_treatment In vitro fertilization Ovarian hyperstimulation syndrome Gonadotropin-Releasing Hormone 0302 clinical medicine Progesterone/blood Pregnancy Medicine Drug Dosage Calculations Progesterone media_common 030219 obstetrics & reproductive medicine Triptorelin Pamoate Oocyte Donation Anti-Mullerian Hormone/blood oocyte donor Obstetrics and Gynecology Oocytes/cytology Triptorelin Treatment Outcome Vietnam Hormone Antagonists/administration & dosage Metaphase/drug effects Ovulation Induction/adverse effects Triptorelin Pamoate/administration & dosage Fertility Agents Female/administration & dosage Female In vitro fertilization gonadotropin-releasing hormone agonist trigger oocyte donor dose-finding triptorelin ovarian hyperstimulation syndrome follicle-stimulating-hormone in-vitro fertilization human chorionic-gonadotropin freeze-all strategy high-risk patients gnrh agonist luteinizing-hormone ovulation induction pregnancy rates Obstetrics & Gynecology Reproductive Biology Luteinizing hormone medicine.drug Adult Ovulation medicine.medical_specialty Adolescent medicine.drug_class media_common.quotation_subject Fertilization in Vitro Gonadotropin-Releasing Hormone/administration & dosage Gonadotropin-releasing hormone antagonist gonadotropin-releasing hormone agonist trigger Andrology 03 medical and health sciences Young Adult Hormone Antagonists Ovulation Induction Gonadotropin-releasing hormone agonist Internal medicine Humans Metaphase In vitro fertilisation business.industry triptorelin Fertility Agents Female Infertility/diagnosis Luteinizing Hormone medicine.disease Antral follicle Embryo Transfer 030104 developmental biology Endocrinology Fertility Ovulation/drug effects Reproductive Medicine Infertility Oocytes Luteinizing Hormone/blood dose-finding business |
| Zdroj: | Ngoc Lan Vuong, T, Tuong Ho, M, Duc Ha, T, Tuan Phung, H, Bao Huynh, G & Humaidan, P 2016, ' Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist : a dose-finding study ', Fertility and Sterility, vol. 105, no. 2, pp. 356-363 . https://doi.org/10.1016/j.fertnstert.2015.10.014 Vuong, T N L, Ho, M T, Ha, T D, Phung, H T, Huynh, G B & Humaidan, P 2016, ' Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist : a dose-finding study ', Fertility and Sterility, vol. 105, no. 2, pp. 356-363 . https://doi.org/10.1016/j.fertnstert.2015.10.014 |
| DOI: | 10.1016/j.fertnstert.2015.10.014 |
| Popis: | OBJECTIVE: To determine the optimal GnRH agonist dose for triggering of oocyte maturation in oocyte donors.DESIGN: Single-center, randomized, parallel, investigator-blinded trial.SETTING: IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam.PATIENT(S): One hundred sixty-five oocyte donors (aged 18-35 years, body mass index [BMI] 1.25 ng/mL, and antral follicle count ≥6).INTERVENTION(S): Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle.MAIN OUTCOME MEASURE(S): The primary end point was number of metaphase II oocytes. Secondary end points were fertilization and cleavage rates, number of embryos and top-quality embryos, steroid levels, ovarian volume, and ongoing pregnancy rate (PR) in recipients.RESULT(S): There were no significant differences between the triptorelin 0.2, 0.3, and 0.4 mg trigger groups with respect to number of metaphase II oocytes (16.0 ± 8.5, 15.9 ± 7.8, and 14.7 ± 8.4, respectively), embryos (13.2 ± 7.8, 11.7 ± 6.9, 11.8 ± 7.0), and number of top-quality embryos (3.8 ± 2.9, 3.6 ± 3.0, 4.1 ± 3.0). Luteinizing hormone levels at 24 hours and 36 hours after trigger was significantly higher with triptorelin 0.4 mg versus 0.2 mg and 0.3 mg (9.8 ± 7.1 IU/L vs. 7.3 ± 4.1 IU/L and 7.2 ± 3.7 IU/L, respectively; 4.6 ± 3.2 IU/L vs. 3.2 ± 2.3 IU/L and 3.3 ± 2.1 IU/L, respectively. Progesterone level at oocyte pick-up +6 days was significantly higher in the 0.4-mg group (2.2 ± 3.7 ng/ml) versus 0.2 mg (1.1 ± 1.0 ng/ml) and 0.3 mg (1.2 ± 1.6 ng/ml). One patient developed early-onset severe ovarian hyperstimulation syndrome (OHSS).CONCLUSION(S): No significant differences between triptorelin doses of 0.2, 0.3, and 0.4 mg used for ovulation trigger in oocyte donors were seen with regard to the number of mature oocytes and top-quality embryos.CLINICAL TRIAL REGISTRATION NUMBER: NCT02208986. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|